Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference

Caribou Biosciences (Nasdaq: CRBU) announced that its management team will participate in a fireside chat at the H.C.

Rhea-AI Summary

Caribou Biosciences (Nasdaq: CRBU) announced that its management team will participate in a fireside chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, 2026 at 12:30 p.m. ET in New York.

A live webcast and replay will be available for at least 30 days on the Events page of Caribou’s website.

Argus May 14 session

+0.94% close to close Open Argus

Details

News Market Reaction – CRBU

In the May 14 session, CRBU gained 0.94%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement adds another investor-relations touchpoint as Caribou Biosciences participates in ...

Analysis

This announcement adds another investor-relations touchpoint as Caribou Biosciences participates in the BioConnect conference on May 19, 2026. It follows recent milestones including RMAT designation for CB-011 and Q1 2026 financials showing a net loss of $25.1M and cash of $118.6M with runway into 2H 2027. Investors may watch for any new clinical or strategic commentary from the fireside chat and subsequent presentations that could refine views on trial timelines and capital planning.

Key Figures

Licensing & other revenue: $2.4M R&D expenses: $20.6M G&A expenses: $8.1M +5 more

Licensing & other revenue

$2.4M

Q1 2026 (10-Q/8-K)

R&D expenses

$20.6M

Q1 2026 (10-Q/8-K)

G&A expenses

$8.1M

Q1 2026 (10-Q/8-K)

Net loss

$25.1M

Q1 2026 (10-Q/8-K)

Cash & securities

$118.6M

As of Mar 31, 2026 (10-Q/8-K)

Licensing revenue

$11.2M

FY 2025 (10-K/earnings)

GAAP net loss

$148.1M

FY 2025 (10-K/earnings)

Cash & securities

$142.8M

As of Dec 31, 2025 (10-K/8-K)

Historical Context

5 past events · Latest: May 12

5 events

1. May 12

   Scientific conference update

   24h Move

   +0.0%

   Plans oral presentations on vispa-cel and CB-011 at EHA 2026.

2. May 07

   Earnings and pipeline

   24h Move

   +3.2%

   Q1 2026 results with FDA alignment on ANTLER-3 and RMAT for CB-011.

3. May 05

   Investor conference

   24h Move

   +1.0%

   Announcement of participation in BofA 2026 Health Care Conference.

4. Mar 31

   Regulatory designation

   24h Move

   +10.5%

   FDA grants RMAT designation to CB-011 based on phase 1 data.

5. Mar 05

   Earnings and pipeline

   24h Move

   +6.4%

   FY2025 results with reduced expenses and strong cash position into 2H 2027.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

crispr, genome-editing

2 terms

crispr medical

"a leading clinical-stage CRISPR genome-editing biopharmaceutical company"

CRISPR is a gene‑editing technology that works like precise molecular scissors to change DNA in living cells. For investors, it matters because it can speed development of new therapies, lower research costs, and create valuable intellectual property, but it also carries scientific, regulatory, ethical, and commercial risks that can strongly affect the value and prospects of companies working with the technology.

genome-editing medical

"a leading clinical-stage CRISPR genome-editing biopharmaceutical company"

Genome-editing is a set of laboratory techniques that make deliberate, targeted changes to an organism’s DNA—like using a word processor to correct, insert, or delete letters in a long instruction manual. For investors it matters because these tools enable new therapies, crops, and diagnostics that can create high-value products and markets, while also bringing technical risk, regulatory review, and ethical debate that influence development timelines, costs, and potential returns.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BERKELEY, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that Caribou’s management team will participate in a fireside chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, 2026, at 12:30pm ET in New York, New York.

For more information and a link to the webcast, visit the Events page on Caribou’s website. Webcasts will be available on the Caribou website for at least 30 days after the event.

About Caribou Biosciences, Inc.
Caribou is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. Caribou’s chRDNA genome-editing technology enables superior precision to develop cell therapies that are armored to potentially improve activity against diseases. Caribou is focused on vispacabtagene regedleucel (vispa-cel) and CB-011 as off-the-shelf CAR-T cell therapies that have the potential to provide broad access and rapid treatment for patients with hematologic malignancies. Follow the company @CaribouBio and visit www.cariboubio.com.

Caribou Biosciences, Inc. contact:
Peggy Vorwald, PhD
investor.relations@cariboubio.com
media@cariboubio.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Caribou Biosciences (CRBU) present at the H.C. Wainwright 4th Annual BioConnect Investor Conference?

Caribou Biosciences will participate in a fireside chat on May 19, 2026 at 12:30 p.m. ET. According to Caribou, the event will take place in New York, New York.

How can investors access the Caribou Biosciences (CRBU) BioConnect conference webcast?

Investors can access the webcast via the Events page on Caribou’s website. According to Caribou, the webcast link and additional event information will be provided there.

Will a replay of the Caribou Biosciences (CRBU) BioConnect fireside chat be available?

Yes, a replay of the fireside chat will be available on Caribou’s website. According to Caribou, webcasts will remain accessible for at least 30 days after the event.

What is the focus of Caribou Biosciences (CRBU) at the H.C. Wainwright 4th Annual BioConnect Investor Conference?

Caribou Biosciences’ management will join a fireside chat with investors at the conference. According to Caribou, the appearance offers an opportunity to discuss its clinical-stage CRISPR genome-editing programs.

Where is the H.C. Wainwright 4th Annual BioConnect Investor Conference featuring Caribou Biosciences (CRBU) being held?

The conference session featuring Caribou Biosciences will be held in New York, New York. According to Caribou, the fireside chat is scheduled there on May 19, 2026.